

## REMARKS


### The Information Disclosure Statement

The accompanying Information Disclosure Statement identifies copending applications assigned to the same Assignee as the present invention which are also directed to aryl ureas and methods for treating cancers mediated by raf kinase. Applicants submit each of these applications should be considered although some may be unpublished or were published after the priority date for this application. A digital copy of the pending claims in these applications has also been provided as well as copies of "Notices of References Cited" and foreign search reports which were issued in some of these related applications.

### No Early Priority Claim

This application, copending application Serial No. 09/993,647 filed on November 27, 2001, and copending application Serial no. 10/042,203, filed January 11, 2002, were all filed without claiming benefit of the earliest possible priority to which they could have been entitled. These applications are drawn to commercially important subject matter whose patentability is especially clear and especially clearly does not need the benefit of such priority. In light of forgoing priority, the current and the other application(s) will, upon issuance, produce patents thus having 20-year terms starting and ending later than they would have if priority were not forsaken.

Respectfully submitted



Richard J. Traverso, Reg. No. 30,595  
Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.  
2200 Clarendon Boulevard  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410  
Attorney Docket No.: BAYER-24A

Date: September 22, 2003

RJT/jqsK:\Bayer\24A\RCE 9-22-03.doc